abstract: UNASSIGNED: 7122 Background: Primary goals of therapy for @entity9 ( @entity9 ) are an increased survival time, palliation of symptoms, and prolonged @entity8 ( @entity8 ). This study was designed to explore if @entity9 @entity0 (pts) with ECOG @entity16 and age <= 65 years could benefit from systemic chemotherapy with acceptable @entity2 . METHODS: Fifty-nine eligible pts with stage IIIB (effusion) or stage IV NSCLC were registered on study. @entity0 received @entity10 ( @entity10  ) 35 mg/m(2) and @entity15 AUC=2 on Days 1, 8, 15 every 28-day cycle (maximum 8 cycles). Endpoints were 1-year survival, @entity1 response, @entity8 , and safety. RESULTS: Among the 59 eligible pts, 1 never received study drug, 58 pts were evaluable for safety, and 49 for response; 9 pts were non-evaluable due to: palliative XRT (1), withdrawal of consent (2), @entity2 (1 each; @entity11 , weakness, @entity7 to study drug) and other illness (3). Responses were: 1 CR (2%), 5 PR (10%), 22 @entity3 (45%), and 21 @entity13 (43%). The 1-year survival was 28%; median survival was 6.0 months (range, <1-24.3). The 1-year progression-free survival was 14% with a median @entity8 of 3.7 months (range, <1-22.8) and median duration of response for CR+PR was 5.4 months (range, 2.3-9.7). @entity0 received a median of 3 cycles (range, 1-9); 14 pts (24%) had dose reductions, mainly due to @entity2 . The primary Grade 3 or 4 @entity2 were @entity12 and fatigue (10.2% each), @entity5 (8.5%), @entity14 (6.8%), and @entity6 (5.1%). All 43 @entity4 were due to @entity13 . @entity2 of this regimen are comparable to other chemotherapy regimens used in this population, thus it may be an alternative treatment choice for @entity0 with @entity9 who are <= 65 years and @entity16 . CONCLUSIONS: These results confirm the relatively poor outcome of @entity16 pts with @entity9 . The overall benefit of chemotherapy doublets, compared to monotherapy, in this @entity0 population remains to be proven. Supported by Aventis Pharmaceuticals, Bridgewater, NJ No significant financial relationships to disclose.

title: A phase II study of weekly @entity10 and XXXX in stage IIIB (with effusion) or stage IV @entity9 @entity0 age < 65 and performance status 2.

answer: @entity15


abstract: UNASSIGNED: 7122 Background: Primary goals of therapy for @entity9 ( @entity9 ) are an increased survival time, palliation of symptoms, and prolonged @entity8 ( @entity8 ). This study was designed to explore if @entity9 @entity0 (pts) with ECOG @entity16 and age <= 65 years could benefit from systemic chemotherapy with acceptable @entity2 . METHODS: Fifty-nine eligible pts with stage IIIB (effusion) or stage IV NSCLC were registered on study. @entity0 received @entity10 ( @entity10  ) 35 mg/m(2) and @entity15 AUC=2 on Days 1, 8, 15 every 28-day cycle (maximum 8 cycles). Endpoints were 1-year survival, @entity1 response, @entity8 , and safety. RESULTS: Among the 59 eligible pts, 1 never received study drug, 58 pts were evaluable for safety, and 49 for response; 9 pts were non-evaluable due to: palliative XRT (1), withdrawal of consent (2), @entity2 (1 each; @entity11 , weakness, @entity7 to study drug) and other illness (3). Responses were: 1 CR (2%), 5 PR (10%), 22 @entity3 (45%), and 21 @entity13 (43%). The 1-year survival was 28%; median survival was 6.0 months (range, <1-24.3). The 1-year progression-free survival was 14% with a median @entity8 of 3.7 months (range, <1-22.8) and median duration of response for CR+PR was 5.4 months (range, 2.3-9.7). @entity0 received a median of 3 cycles (range, 1-9); 14 pts (24%) had dose reductions, mainly due to @entity2 . The primary Grade 3 or 4 @entity2 were @entity12 and fatigue (10.2% each), @entity5 (8.5%), @entity14 (6.8%), and @entity6 (5.1%). All 43 @entity4 were due to @entity13 . @entity2 of this regimen are comparable to other chemotherapy regimens used in this population, thus it may be an alternative treatment choice for @entity0 with @entity9 who are <= 65 years and @entity16 . CONCLUSIONS: These results confirm the relatively poor outcome of @entity16 pts with @entity9 . The overall benefit of chemotherapy doublets, compared to monotherapy, in this @entity0 population remains to be proven. Supported by Aventis Pharmaceuticals, Bridgewater, NJ No significant financial relationships to disclose.

title: A phase II study of weekly @entity10 and @entity15 in stage IIIB (with effusion) or stage IV @entity9 XXXX age < 65 and performance status 2.

answer: @entity0


abstract: UNASSIGNED: Purpose To develop and independently validate prognostic imaging biomarkers for predicting survival in @entity0 with @entity2 on the basis of multiregion quantitative image analysis. Materials and Methods This retrospective study was approved by the local institutional review board, and informed consent was waived. A total of 79 @entity0 from two independent cohorts were included. The discovery and validation cohorts consisted of 46 and 33 @entity0 with @entity2 from the Cancer Imaging Archive (TCIA) and the local institution, respectively. Preoperative T1-weighted contrast material-enhanced and T2-weighted fluid-attenuation inversion recovery magnetic resonance (MR) images were analyzed. For each @entity0 , we semiautomatically delineated the @entity1 and performed automated intratumor segmentation, dividing the @entity1 into spatially distinct subregions that demonstrate coherent intensity patterns across multiparametric MR imaging. Within each subregion and for the entire @entity1 , we extracted quantitative imaging features, including those that fully capture the differential contrast of multimodality MR imaging. A multivariate sparse Cox regression model was trained by using TCIA data and tested on the validation cohort. Results The optimal prognostic model identified five imaging biomarkers that quantified @entity1 surface area and intensity distributions of the @entity1 and its subregions. In the validation cohort, our prognostic model achieved a concordance index of 0.67 and significant stratification of overall survival by using the log-rank test (P = .018), which outperformed conventional prognostic factors, such as age (concordance index, 0.57; P = .389) and @entity1 volume (concordance index, 0.59; P = .409). Conclusion The multiregion analysis presented here establishes a general strategy to effectively characterize intratumor heterogeneity manifested at multimodality imaging and has the potential to reveal useful prognostic imaging biomarkers in @entity2 . (  ) RSNA, 2015 Online supplemental material is available for this article.

title: Prognostic Imaging Biomarkers in XXXX : Development and Independent Validation on the Basis of Multiregion and Quantitative Analysis of MR Images.

answer: @entity2


abstract: UNASSIGNED: 4120 Background: The @entity9 ( @entity9 ) enzyme is overexpressed in 45-72% of @entity5 . Inhibition of the @entity9 sensitises @entity0 @entity5 cells to the apoptotic effects of cytotoxic. @entity1 by fixed dose rate infusion may improve response rate and survival in @entity0 with @entity5 . This phase II study was undertaken to determine the effects of adding @entity10 to a regimen of @entity1 by fixed dose rate infusion and @entity7 . METHODS: The primary endpoint was survival at 6 months in @entity0 with metastatic @entity5 treated with the @entity1 , @entity7 , and @entity10 regimen. Previously untreated @entity0 with a performance status of 0-2 were eligible for this study. @entity0 received @entity1 1,000 mg/m(2) by fixed dose rate (10 mg/m(2)/min) I.V. infusion, and @entity7 35 mg/m(2) on days 1 and 8 of a 21-day cycle. @entity10 was administered at a dose 400 mg twice-daily continuously starting day -7 until termination from study. RESULTS: A total of 22 @entity0 (median age 59 years; males 13%) were enrolled on the study. Median performance status was 1. The median number of cycles administered was 2 (range 0-11). Seventeen @entity0 were response evaluable. In intent to treat analysis, objective response and stable disease were seen in 9% (90% CI; 0.02-0.24) and 27%, respectively. Nine @entity0 were alive at 6-months. Median overall survival time was 5.7 months (90% CI; 3.7-7.5 months). No treatment related @entity3 were observed. The most commonly reported grade 3/4 @entity2 were @entity8 (65%), @entity6 (55%), and @entity4 (35%). The majority of the @entity0 required dose reductions of @entity1 and @entity7 . CONCLUSION: @entity10 can be safely administered in combination with @entity1 and @entity7 . The regimen of @entity1 by the fixed dose rate infusion and @entity7 was associated with significant myelosuppression. The addition of @entity10 to a regimen utilizing @entity1 by fixed dose rate infusion did not appear to have a significant impact on the 6-month survival rate and overall survival. No significant financial relationships to disclose.

title: A phase II study of @entity1 by fixed-dose rate infusion, XXXX , and @entity10 in metastatic @entity5 .

answer: @entity7


abstract: UNASSIGNED: 4120 Background: The @entity9 ( @entity9 ) enzyme is overexpressed in 45-72% of @entity5 . Inhibition of the @entity9 sensitises @entity0 @entity5 cells to the apoptotic effects of cytotoxic. @entity1 by fixed dose rate infusion may improve response rate and survival in @entity0 with @entity5 . This phase II study was undertaken to determine the effects of adding @entity10 to a regimen of @entity1 by fixed dose rate infusion and @entity7 . METHODS: The primary endpoint was survival at 6 months in @entity0 with metastatic @entity5 treated with the @entity1 , @entity7 , and @entity10 regimen. Previously untreated @entity0 with a performance status of 0-2 were eligible for this study. @entity0 received @entity1 1,000 mg/m(2) by fixed dose rate (10 mg/m(2)/min) I.V. infusion, and @entity7 35 mg/m(2) on days 1 and 8 of a 21-day cycle. @entity10 was administered at a dose 400 mg twice-daily continuously starting day -7 until termination from study. RESULTS: A total of 22 @entity0 (median age 59 years; males 13%) were enrolled on the study. Median performance status was 1. The median number of cycles administered was 2 (range 0-11). Seventeen @entity0 were response evaluable. In intent to treat analysis, objective response and stable disease were seen in 9% (90% CI; 0.02-0.24) and 27%, respectively. Nine @entity0 were alive at 6-months. Median overall survival time was 5.7 months (90% CI; 3.7-7.5 months). No treatment related @entity3 were observed. The most commonly reported grade 3/4 @entity2 were @entity8 (65%), @entity6 (55%), and @entity4 (35%). The majority of the @entity0 required dose reductions of @entity1 and @entity7 . CONCLUSION: @entity10 can be safely administered in combination with @entity1 and @entity7 . The regimen of @entity1 by the fixed dose rate infusion and @entity7 was associated with significant myelosuppression. The addition of @entity10 to a regimen utilizing @entity1 by fixed dose rate infusion did not appear to have a significant impact on the 6-month survival rate and overall survival. No significant financial relationships to disclose.

title: A phase II study of @entity1 by fixed-dose rate infusion, @entity7 , and XXXX in metastatic @entity5 .

answer: @entity10


abstract: UNASSIGNED: 4120 Background: The @entity9 ( @entity9 ) enzyme is overexpressed in 45-72% of @entity5 . Inhibition of the @entity9 sensitises @entity0 @entity5 cells to the apoptotic effects of cytotoxic. @entity1 by fixed dose rate infusion may improve response rate and survival in @entity0 with @entity5 . This phase II study was undertaken to determine the effects of adding @entity10 to a regimen of @entity1 by fixed dose rate infusion and @entity7 . METHODS: The primary endpoint was survival at 6 months in @entity0 with metastatic @entity5 treated with the @entity1 , @entity7 , and @entity10 regimen. Previously untreated @entity0 with a performance status of 0-2 were eligible for this study. @entity0 received @entity1 1,000 mg/m(2) by fixed dose rate (10 mg/m(2)/min) I.V. infusion, and @entity7 35 mg/m(2) on days 1 and 8 of a 21-day cycle. @entity10 was administered at a dose 400 mg twice-daily continuously starting day -7 until termination from study. RESULTS: A total of 22 @entity0 (median age 59 years; males 13%) were enrolled on the study. Median performance status was 1. The median number of cycles administered was 2 (range 0-11). Seventeen @entity0 were response evaluable. In intent to treat analysis, objective response and stable disease were seen in 9% (90% CI; 0.02-0.24) and 27%, respectively. Nine @entity0 were alive at 6-months. Median overall survival time was 5.7 months (90% CI; 3.7-7.5 months). No treatment related @entity3 were observed. The most commonly reported grade 3/4 @entity2 were @entity8 (65%), @entity6 (55%), and @entity4 (35%). The majority of the @entity0 required dose reductions of @entity1 and @entity7 . CONCLUSION: @entity10 can be safely administered in combination with @entity1 and @entity7 . The regimen of @entity1 by the fixed dose rate infusion and @entity7 was associated with significant myelosuppression. The addition of @entity10 to a regimen utilizing @entity1 by fixed dose rate infusion did not appear to have a significant impact on the 6-month survival rate and overall survival. No significant financial relationships to disclose.

title: A phase II study of @entity1 by fixed-dose rate infusion, @entity7 , and @entity10 in metastatic XXXX .

answer: @entity5


abstract: UNASSIGNED: 4120 Background: The @entity9 ( @entity9 ) enzyme is overexpressed in 45-72% of @entity5 . Inhibition of the @entity9 sensitises @entity0 @entity5 cells to the apoptotic effects of cytotoxic. @entity1 by fixed dose rate infusion may improve response rate and survival in @entity0 with @entity5 . This phase II study was undertaken to determine the effects of adding @entity10 to a regimen of @entity1 by fixed dose rate infusion and @entity7 . METHODS: The primary endpoint was survival at 6 months in @entity0 with metastatic @entity5 treated with the @entity1 , @entity7 , and @entity10 regimen. Previously untreated @entity0 with a performance status of 0-2 were eligible for this study. @entity0 received @entity1 1,000 mg/m(2) by fixed dose rate (10 mg/m(2)/min) I.V. infusion, and @entity7 35 mg/m(2) on days 1 and 8 of a 21-day cycle. @entity10 was administered at a dose 400 mg twice-daily continuously starting day -7 until termination from study. RESULTS: A total of 22 @entity0 (median age 59 years; males 13%) were enrolled on the study. Median performance status was 1. The median number of cycles administered was 2 (range 0-11). Seventeen @entity0 were response evaluable. In intent to treat analysis, objective response and stable disease were seen in 9% (90% CI; 0.02-0.24) and 27%, respectively. Nine @entity0 were alive at 6-months. Median overall survival time was 5.7 months (90% CI; 3.7-7.5 months). No treatment related @entity3 were observed. The most commonly reported grade 3/4 @entity2 were @entity8 (65%), @entity6 (55%), and @entity4 (35%). The majority of the @entity0 required dose reductions of @entity1 and @entity7 . CONCLUSION: @entity10 can be safely administered in combination with @entity1 and @entity7 . The regimen of @entity1 by the fixed dose rate infusion and @entity7 was associated with significant myelosuppression. The addition of @entity10 to a regimen utilizing @entity1 by fixed dose rate infusion did not appear to have a significant impact on the 6-month survival rate and overall survival. No significant financial relationships to disclose.

title: A phase II study of XXXX by fixed-dose rate infusion, @entity7 , and @entity10 in metastatic @entity5 .

answer: @entity1


abstract: UNASSIGNED: 8508 Background: Long-term outcomes of @entity0 with @entity6 treated on cooperative group trials need to be defined. METHODS: We assessed late mortality [death occurring 5+ years (yrs) after diagnosis (dx)] in a retrospective cohort of 8,444 @entity0 (pts), with @entity6 , treated on @entity0 's Oncology Group (COG) therapeutic protocols between 1979 and 1990. Vital status was determined using medical records, National Death Index, and Social Security Death Index. Age- and sex-standardized mortality ratios (SMR) were calculated using US population mortality data. RESULTS: A total of 6,424 pts (56% males, 80% Caucasians) survived 5+ yrs. Median age at dx was 4.6 yrs, and 15.6 yrs at follow-up. 549 @entity2 occurred 5+ yrs from dx with @entity1 , @entity3 and @entity4 accounting for 65%. Multivariate analysis revealed risk of relapse-related mortality to be lower in females (Relative Risk (RR)=0.8, p=0.03), dx at age 1 to 10 yrs (RR=0.5, p=0.02) and dx after 1985 (RR=0.6, p=0.01). Non-relapse-related mortality was lower among females (RR=0.7, p=0.02). The cohort was at a 7.5-fold increased risk of late death when compared with the general population (Table). Overall survival at 20 years was 91%, 99%, and 99.4% for 5+, 10+ and 15+ yr survivors, respectively. Therapeutic summaries were available for a subcohort of 2,929 5-yr survivors treated between 1983-1989. The overall survival was 91.5% at 15 yrs, and the subcohort was at a 7.8-fold risk of late death. @entity7 (>200 mg/m(2): RR=0.6, p=0.07) and @entity5 (>2000 mg/m(2): RR=0.7, p=0.06) offered protection against 5+ yr relapse-related mortality. @entity7 did not increase the risk of @entity2 due to cardiac causes. CONCLUSIONS: At 15 yrs from dx, risk of late death is no longer elevated among @entity6 survivors. [Figure: see text] No significant financial relationships to disclose.

title: Late mortality after childhood @entity6 ( XXXX ).

answer: @entity6


abstract: UNASSIGNED: 8508 Background: Long-term outcomes of @entity0 with @entity6 treated on cooperative group trials need to be defined. METHODS: We assessed late mortality [death occurring 5+ years (yrs) after diagnosis (dx)] in a retrospective cohort of 8,444 @entity0 (pts), with @entity6 , treated on @entity0 's Oncology Group (COG) therapeutic protocols between 1979 and 1990. Vital status was determined using medical records, National Death Index, and Social Security Death Index. Age- and sex-standardized mortality ratios (SMR) were calculated using US population mortality data. RESULTS: A total of 6,424 pts (56% males, 80% Caucasians) survived 5+ yrs. Median age at dx was 4.6 yrs, and 15.6 yrs at follow-up. 549 @entity2 occurred 5+ yrs from dx with @entity1 , @entity3 and @entity4 accounting for 65%. Multivariate analysis revealed risk of relapse-related mortality to be lower in females (Relative Risk (RR)=0.8, p=0.03), dx at age 1 to 10 yrs (RR=0.5, p=0.02) and dx after 1985 (RR=0.6, p=0.01). Non-relapse-related mortality was lower among females (RR=0.7, p=0.02). The cohort was at a 7.5-fold increased risk of late death when compared with the general population (Table). Overall survival at 20 years was 91%, 99%, and 99.4% for 5+, 10+ and 15+ yr survivors, respectively. Therapeutic summaries were available for a subcohort of 2,929 5-yr survivors treated between 1983-1989. The overall survival was 91.5% at 15 yrs, and the subcohort was at a 7.8-fold risk of late death. @entity7 (>200 mg/m(2): RR=0.6, p=0.07) and @entity5 (>2000 mg/m(2): RR=0.7, p=0.06) offered protection against 5+ yr relapse-related mortality. @entity7 did not increase the risk of @entity2 due to cardiac causes. CONCLUSIONS: At 15 yrs from dx, risk of late death is no longer elevated among @entity6 survivors. [Figure: see text] No significant financial relationships to disclose.

title: Late mortality after childhood XXXX ( @entity6 ).

answer: @entity6


abstract: UNASSIGNED: 4135 Background: Both surgical resection and local ablation therapy such as PEI have been widely used for @entity0 (pts) with small @entity3 . Each treatment is selected mainly according to the technical feasibility of treatment because retrospective data suggest that the two treatments are comparable in terms of survival. To assess longitudinal changes in treatment strategy for small @entity3 , two retrospective comparative studies were conducted in the 4 major center hospitals where pretreatment conferences are well organized by surgeons and nonsurgical specialists for PEI. METHODS: Clinical information on the @entity0 characteristics was compared between @entity0 with newly diagnosed small @entity3 (smaller than 3 cm and 3 or less in number) in 1990-1994 and 1998-1999 who underwent surgery or PEI before introduction of radiofrequency ablation therapy in each hospital. Long-term results with reference to their survival significance were also analyzed. RESULTS: Of the 97 pts in 1990-1994, 58 (60%) underwent surgery and 39 (40%) were treated with PEI. In the 151 pts in 1998-1999, 95 (63%) were surgically treated and 56 (37%) received PEI. No significant differences in @entity0 characteristics between the 1990-1994 pts and the 1998-1999 pts were observed except for a better @entity4 level in the 1998-1999 pts. In the surgical pts, the 1998-1999 pts included more pts with solitary @entity1 and showed better hepatic reserve according to the ICG test, and better albumin and @entity4 levels compared to the 1990-1994 pts. In the PEI pts, the 1998-1999 pts were older and included more pts with @entity2 than the 1990-1994 pts. Although the overall survival rates were identical between the 1990-1994 pts and the 1998-1999 pts, the 1998-1999 surgical pts survived significantly longer (p=0.03), and the PEI pts tended to survive shorter (p=0.09) compared to the 1990-1994 pts. CONCLUSIONS: This study suggests that either surgery or PEI is being selected according to risk of surgical morbidity is being promoted, resulting in longitudinal changes in outcome of pts treated with each approach. No significant financial relationships to disclose.

title: Longitudinal comparisons of results in surgical resection and percutaneous ethanol injection therapy (PEI): Change in treatment strategy for @entity3 ( XXXX ).

answer: @entity3


abstract: UNASSIGNED: 4135 Background: Both surgical resection and local ablation therapy such as PEI have been widely used for @entity0 (pts) with small @entity3 . Each treatment is selected mainly according to the technical feasibility of treatment because retrospective data suggest that the two treatments are comparable in terms of survival. To assess longitudinal changes in treatment strategy for small @entity3 , two retrospective comparative studies were conducted in the 4 major center hospitals where pretreatment conferences are well organized by surgeons and nonsurgical specialists for PEI. METHODS: Clinical information on the @entity0 characteristics was compared between @entity0 with newly diagnosed small @entity3 (smaller than 3 cm and 3 or less in number) in 1990-1994 and 1998-1999 who underwent surgery or PEI before introduction of radiofrequency ablation therapy in each hospital. Long-term results with reference to their survival significance were also analyzed. RESULTS: Of the 97 pts in 1990-1994, 58 (60%) underwent surgery and 39 (40%) were treated with PEI. In the 151 pts in 1998-1999, 95 (63%) were surgically treated and 56 (37%) received PEI. No significant differences in @entity0 characteristics between the 1990-1994 pts and the 1998-1999 pts were observed except for a better @entity4 level in the 1998-1999 pts. In the surgical pts, the 1998-1999 pts included more pts with solitary @entity1 and showed better hepatic reserve according to the ICG test, and better albumin and @entity4 levels compared to the 1990-1994 pts. In the PEI pts, the 1998-1999 pts were older and included more pts with @entity2 than the 1990-1994 pts. Although the overall survival rates were identical between the 1990-1994 pts and the 1998-1999 pts, the 1998-1999 surgical pts survived significantly longer (p=0.03), and the PEI pts tended to survive shorter (p=0.09) compared to the 1990-1994 pts. CONCLUSIONS: This study suggests that either surgery or PEI is being selected according to risk of surgical morbidity is being promoted, resulting in longitudinal changes in outcome of pts treated with each approach. No significant financial relationships to disclose.

title: Longitudinal comparisons of results in surgical resection and percutaneous ethanol injection therapy (PEI): Change in treatment strategy for XXXX ( @entity3 ).

answer: @entity3


abstract: @entity7 is caused by @entity1 in the cellular metabolism of @entity3 (C) and is characterized by high levels of low-density lipoproteins (LDL) and premature @entity4 . The C is carried in the plasma mainly as an LDL-C complex, and removal of the latter from plasma is highly desirable. This task can be achieved by selective haemoperfusion (HP), thereby eliminating the need for plasmapheresis. Agarose beads (2 per cent agarose, 0.85 to 1.4 mm in diameter) were prepared, and crosslinked with @entity9 . Heparin and/or @entity8 were subsequently attached. The beads thus obtained were found to be suitable for the removal of LDL-C from the whole blood of hypercholesterolaemic @entity2 , using a simple HP technique. A single two-hour HP treatment with a 40 ml column packed with active agarose beads resulted in a 30 per cent decrease in the C plasma level in the experimental animals. Our previous, in vitro, studies with the plasma of hypercholesterolaemic @entity0 showed a high selectivity of the beads for LDL. Yet when used with hypercholesterolaemic @entity2 , a relatively high amount of HDL was also removed from the blood. This can be attributed to a significant difference between the structure of @entity0 @entity6 and that of @entity2 . Upon treatment of blood using the active agarose beads, no @entity5 were detected, except for some prolongation of PT. It is to be hoped that this new system will replace the presently used and highly expensive plasmapheresis.

title: XXXX removal by haemoperfusion of whole blood in vivo.

answer: @entity3


abstract: PURPOSE: To determine differences in tibial tubercle-trochlear groove (TT-TG) distance between @entity0 with a history of noncontact anterior cruciate ligament (ACL) injury and an uninjured control group. METHODS: MRI studies of 60 @entity0 (age range, 14 to 25 years) with @entity2 ( @entity2 ) knees were compared with 60 intact-ACL controls. All @entity0 underwent MRI after a noncontact @entity3 . TT-TG distances were measured on proton density-weighted axial images. Independent t-tests were used to determine differences in TT-TG distance between the @entity2 and control groups. RESULTS: The mean TT-TG distance in the @entity2 group was 12.07 mm (95% confidence interval [CI], 11.11 to  13.02), compared with 10.44 mm (95% CI, 9.64 to 11.24) in the control group. The mean TT-TG distance in the male @entity2 group was 12.95 mm (95% CI, 11.39 to 14.51), compared with 10.87 mm (95% CI, 9.52 to 12.21) in the male control group. The mean TT-TG distance in the female @entity2 group was 11.48 mm (95% CI, 10.24 to 12.71), compared with 10.04 mm (95% CI, 9.06 to 11.02) in the female control group. There were statistically significant differences in TT-TG distance between the @entity2 and control groups (P  = .011) and between the male @entity2 and control groups (P  =  .041). CONCLUSIONS: In adolescents and young adults, the TT-TG distance was statistically larger in knees with noncontact ACL tears than in intact-ACL control knees. When the groups were stratified on the basis of sex, only the male @entity0 showed a statistical difference, with a 2.08 mm increase in TT-TG distance between the @entity2 and intact-ACL @entity0 . No difference in TT-TG distance was found between the @entity2 and control groups for female @entity0 . Despite the findings of this study, the clinical significance of an increased TT-TG distance as an isolated risk factor for noncontact @entity1 remains unanswered. LEVEL OF EVIDENCE: Level III, case-control study.

title: The Relationship Between Tibial Tubercle-Trochlear Groove Distance and Noncontact Anterior Cruciate XXXX in Adolescents and Young Adults.

answer: @entity1


abstract: BACKGROUND: Little is known about the metastatic potential of low-grade @entity4 . This study was designed to evaluate the rate of @entity1 to identify possible risk factors. METHODS: The files of 225 @entity0 with newly diagnosed, grade I @entity3 treated between 1975 and 2012 were retrospectively analyzed. Median follow-up was 80  months for survivors (range 24-445  months). Nonparametric analyses were performed with the Mann-Whitney U test. Survival curves were calculated with the Kaplan-Meier method and compared with the log-rank test. RESULTS: Fourteen @entity0 developed @entity1 after a median of 49  months. @entity1 ( @entity1 ) was 95  % at 5  years and 92  % at 10  years. Post- @entity1 survival probability amounted to 27  % after 5  years. @entity2 size at diagnosis (P  =  0.698) and surgical margin width (P  =  0.514) had no influence on @entity1 . @entity0 who developed local recurrences had a significantly lower 10-year @entity1 than @entity0 without recurrences (69  % vs. 99  %, P  <  0.001). @entity0 with grade I recurrences had a significantly poorer @entity1 than @entity0 without recurrences (P  =  0.013) but a significantly higher @entity1 than @entity0 with grade II recurrences (P  =  0.006). @entity0 with @entity2 had a significantly lower 10-year @entity1 of 66  % compared with @entity0 with @entity2 of the upper (100  %, P  <  0.001) and lower extremity (93  %, P  =  0.033). CONCLUSIONS: The biological behavior of low-grade @entity4 appears to be more consistent with the WHO definition of rarely metastasizing @entity5 , rather than the one of locally aggressive @entity2 . @entity2 and the development of local recurrences were associated with a higher @entity1 rate in this study.

title: Metastatic Potential of Grade I XXXX : Results of a Multi-institutional Study.

answer: @entity3


abstract: BACKGROUND: This study aimed to evaluate the feasibility and effectiveness of ultrasound-guided charcoal tattooing in locating metastatic lymph nodes in robotic selective neck dissection (SND) for @entity2 ( @entity2 ). METHODS: The overall study group comprised 21 @entity0 with @entity2 who underwent robotic SND via a unilateral transaxillary approach for treatment of suspicious lymph node @entity1 in the lateral compartment. Charcoal suspension was injected into 10 of the @entity0 (total of 23 lesions) 1 day before robotic SND. The authors evaluated the location of the tattoos, the success rate of localization, the intraoperative detection rate, and the complications associated with the procedure. The perioperative results were compared with those in the control group of 11 @entity0 who did not receive charcoal tattooing. RESULTS: Charcoal suspension was successfully injected into 22 of the 23 suspicious lymph nodes (95.7 %). The remaining lesion was located posterior to the internal jugular vein. Therefore, the @entity3 was injected into the soft tissue around the lymph node. Ultrasound-guided injections were well tolerated in all the @entity0 , and no major complications occurred. All the charcoal-tattooed lesions were identified intraoperatively by the surgeon. The number of harvested and metastatic lymph nodes in the lateral compartment was greater in the @entity0 with charcoal tattoo localization than in the control group. The two groups did not differ in terms of perioperative complications, operation time, or volume of drainage. CONCLUSION: Ultrasound-guided charcoal tattooing for localization of metastatic lymph nodes is feasible and effective in robotic SND for the treatment of @entity2 with lateral compartment lymph node @entity1 .

title: Feasibility of Charcoal Tattooing for Localization of Metastatic Lymph Nodes in Robotic Selective Neck Dissection for XXXX .

answer: @entity2


abstract: UNASSIGNED: @entity5 ( @entity5 ) remains the most common cause of poor visual outcome following @entity3 surgery. Whereas acute @entity5 may resolve itself spontaneously, some @entity0 will suffer from @entity2 and will be difficult to treat. Although @entity5 has already been described approximately 50 years ago, its pathophysiology remains uncertain and a multitude of mechanisms have been suggested. As broad as the mechanisms, as many are the treatment options. Topical nonsteroidal anti-inflammatory agents (NSAIDs) and @entity4 either as mono- or combined therapy are a commonly used first line approach. When ineffective, systemic treatment with these agents may be an option. Alternatively, intravitreal application of corticosteroids and anti-vascular endothelial growth factor (anti- @entity1 ) may offer an effective option, if first-line treatment fails. A critical evaluation of the current literature revealed that the optimal treatment of @entity5 remains unclear and requires further investigation. In addition, prevention should be of foremost importance and remains an open issue. Identification of risk factors, application of NSAIDs and consequent follow-up are potential essential steps in the avoidance of this complication.

title: Controversies in NSAIDs use in XXXX surgery.

answer: @entity3


abstract: INTRODUCTION: @entity8 ( @entity8 ) shows a propensity for extending into the tributaries of the renal veins, which poses a notable surgical challenge. In this study we addressed the question as to whether @entity0 with @entity8 and vein involvement can be identified as having a significant risk of immediate @entity3 associated with surgery preoperatively. MATERIALS AND METHODS: A total of 118 @entity0 with @entity8 and vein involvement from February 1999 until November 2012 were evaluated. The association of early mortality within 60  days after the intervention was tested with various covariates including: age, body mass index (BMI), preoperative serum @entity9 , preoperative serum @entity7 , preoperative hemoglobin level, @entity2 diameter, suspicion of @entity1 on prior computed tomography, documented @entity4 , extent of vein invasion, prior @entity5 , @entity10 stage, American Society of Anesthesiologists score, New York Heart Association classification and Karnofsky index. A multiple logistic regression model was used to test all risk factors including the combination of an elevated BMI with an impaired Karnofsky index with all covariates. RESULTS: A total of 17 @entity0 died within 60  days after the operation with most @entity0 dying from @entity6 during the first two quartiles of the observation, while later deaths were mostly attributable to sequelae of surgical complications. None of the tested risk factors were significantly associated with early mortality in the logistic regression model. The presence of an elevated BMI (>= 30  kg/m(2)) in combination with a Karnofsky index  <=70% predicted @entity3 in univariate (p  =  0.006) and multivariate analysis (p  =  0.023). @entity3 rates for @entity0 with BMI  <30  kg/m(2) and Karnofsky index  >70%, BMI  >=   30  kg/m(2) or Karnofsky index   <=70%, BMI  >= 30  kg/m(2) and Karnofsky index   <=70% were 5%, 14.8% and 37.5%, respectively. CONCLUSION: The risk of @entity3 is dramatically elevated to more than one-third of cases with elevated BMI and unfavorable Karnofsky index in @entity0 with @entity8 and vein involvement. @entity0 need to be counseled in this regard especially when planning cytoreductive treatment without curative intent.

title: Prediction of Perioperative @entity3 Following Surgery for XXXX with Vein Involvement: A Retrospective Study.

answer: @entity8


abstract: INTRODUCTION: @entity8 ( @entity8 ) shows a propensity for extending into the tributaries of the renal veins, which poses a notable surgical challenge. In this study we addressed the question as to whether @entity0 with @entity8 and vein involvement can be identified as having a significant risk of immediate @entity3 associated with surgery preoperatively. MATERIALS AND METHODS: A total of 118 @entity0 with @entity8 and vein involvement from February 1999 until November 2012 were evaluated. The association of early mortality within 60  days after the intervention was tested with various covariates including: age, body mass index (BMI), preoperative serum @entity9 , preoperative serum @entity7 , preoperative hemoglobin level, @entity2 diameter, suspicion of @entity1 on prior computed tomography, documented @entity4 , extent of vein invasion, prior @entity5 , @entity10 stage, American Society of Anesthesiologists score, New York Heart Association classification and Karnofsky index. A multiple logistic regression model was used to test all risk factors including the combination of an elevated BMI with an impaired Karnofsky index with all covariates. RESULTS: A total of 17 @entity0 died within 60  days after the operation with most @entity0 dying from @entity6 during the first two quartiles of the observation, while later deaths were mostly attributable to sequelae of surgical complications. None of the tested risk factors were significantly associated with early mortality in the logistic regression model. The presence of an elevated BMI (>= 30  kg/m(2)) in combination with a Karnofsky index  <=70% predicted @entity3 in univariate (p  =  0.006) and multivariate analysis (p  =  0.023). @entity3 rates for @entity0 with BMI  <30  kg/m(2) and Karnofsky index  >70%, BMI  >=   30  kg/m(2) or Karnofsky index   <=70%, BMI  >= 30  kg/m(2) and Karnofsky index   <=70% were 5%, 14.8% and 37.5%, respectively. CONCLUSION: The risk of @entity3 is dramatically elevated to more than one-third of cases with elevated BMI and unfavorable Karnofsky index in @entity0 with @entity8 and vein involvement. @entity0 need to be counseled in this regard especially when planning cytoreductive treatment without curative intent.

title: Prediction of Perioperative XXXX Following Surgery for @entity8 with Vein Involvement: A Retrospective Study.

answer: @entity3


abstract: UNASSIGNED: Our study aimed at the investigation of in vivo anticancer effect of the combination use of @entity2 ( @entity4 ) and @entity1 ( @entity5 ) as well as the development of pharmacokinetic/pharmacodynamic (PK/ @entity3 ) models in MCF-7 xenograft model. Further, simulations were conducted to optimize doses and administration schedules. The inhibitory effect of different doses and administration schedules were investigated in MCF-7 xenograft model. Semi-mechanism-based PK/ @entity3 models were established based on the preclinical data to characterize the relationship between plasma concentration and the time course of the drug response quantitatively. The PK/ @entity3 models were further applied to predict and optimize doses and administration schedules, which would lead to @entity0 stasis by the end of the treatment. Synergistic effect was observed in the @entity3 study in vivo and further confirmed by the estimated combination index    obtained from PK/ @entity3 models. The optimum dose regimen was selected as @entity4 2 mg/kg, qd and @entity5 10 mg/kg, q2d based on the simulation results. In summary, the @entity3 interaction between @entity4 and @entity5 was demonstrated as synergism by both experimental results and modeling approach. Dosage regimens were optimized as predicted by modeling and simulations, which would provide reference for preclinical study and translational research as well.    2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:4399-4408, 2015.

title: Semi-Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for the Combination Use of XXXX and @entity1 in Breast Cancer.

answer: @entity2


abstract: UNASSIGNED: Our study aimed at the investigation of in vivo anticancer effect of the combination use of @entity2 ( @entity4 ) and @entity1 ( @entity5 ) as well as the development of pharmacokinetic/pharmacodynamic (PK/ @entity3 ) models in MCF-7 xenograft model. Further, simulations were conducted to optimize doses and administration schedules. The inhibitory effect of different doses and administration schedules were investigated in MCF-7 xenograft model. Semi-mechanism-based PK/ @entity3 models were established based on the preclinical data to characterize the relationship between plasma concentration and the time course of the drug response quantitatively. The PK/ @entity3 models were further applied to predict and optimize doses and administration schedules, which would lead to @entity0 stasis by the end of the treatment. Synergistic effect was observed in the @entity3 study in vivo and further confirmed by the estimated combination index    obtained from PK/ @entity3 models. The optimum dose regimen was selected as @entity4 2 mg/kg, qd and @entity5 10 mg/kg, q2d based on the simulation results. In summary, the @entity3 interaction between @entity4 and @entity5 was demonstrated as synergism by both experimental results and modeling approach. Dosage regimens were optimized as predicted by modeling and simulations, which would provide reference for preclinical study and translational research as well.    2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:4399-4408, 2015.

title: Semi-Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for the Combination Use of @entity2 and XXXX in Breast Cancer.

answer: @entity1


abstract: In an approach to understanding the origin of @entity2 resistance in clinical isolates of staphylococci, a series of @entity1 mutants resistant to various @entity3 antibiotics were isolated in the laboratory by antibiotic selection. Mutants with low- and intermediate-level resistance showed considerable specificity for the particular antibiotic used in the selection process ( @entity2 , @entity4 , @entity5 , and @entity6 ), and resistance in such mutants also showed alterations in the antibiotic binding capacities of @entity0 -binding proteins (PBPs). In each case the isolation of mutants resistant to high concentrations of antibiotics required sequential passage in gradually increasing concentrations of the drug. The acquisition of increasing levels of @entity2 resistance was paralleled by a gradual decrease in the binding capacities of PBPs 2, 3, and, possibly, 1. In a highly @entity2 -resistant mutant (MIC, 150 micrograms/ml), PBPs 2 and 3 were no longer detectable by the @entity0 binding assay. Instead, a new PBP of poor binding capacity and anomalous molecular size (about 78 kilodaltons [kDa]) appeared in these cells. This corresponds to the molecular size of PBP 2a, the unique PBP that appears to be the biochemical correlate of resistance in clinical isolates of @entity2 -resistant @entity1 . Also, similar to the case of resistant clinical isolates, high-level @entity3 resistance was highly pH dependent in the laboratory mutants. We compared the patterns of radioactive peptides generated by partial proteolysis from the @entity0 -labeled PBP 2 of antibiotic-susceptible staphylococci and from the 78-kDa PBP 2a of a resistant clinical strain. Although the patterns were clearly different, seven of the eight characteristic peptides generated from PBP 2 of the susceptible strain were also detectable among the peptides released from PBP 2a. The results suggest that the 78-kDa PBP 2a of the resistant clinical strain evolved from PBP 2 of antibiotic-susceptible staphylococci and that in PBP 2a of the clinical isolate mutational changes have resulted in extensive alterations near the @entity3 binding site.

title: @entity3 -specific resistant mutants of XXXX .

answer: @entity1


abstract: In an approach to understanding the origin of @entity2 resistance in clinical isolates of staphylococci, a series of @entity1 mutants resistant to various @entity3 antibiotics were isolated in the laboratory by antibiotic selection. Mutants with low- and intermediate-level resistance showed considerable specificity for the particular antibiotic used in the selection process ( @entity2 , @entity4 , @entity5 , and @entity6 ), and resistance in such mutants also showed alterations in the antibiotic binding capacities of @entity0 -binding proteins (PBPs). In each case the isolation of mutants resistant to high concentrations of antibiotics required sequential passage in gradually increasing concentrations of the drug. The acquisition of increasing levels of @entity2 resistance was paralleled by a gradual decrease in the binding capacities of PBPs 2, 3, and, possibly, 1. In a highly @entity2 -resistant mutant (MIC, 150 micrograms/ml), PBPs 2 and 3 were no longer detectable by the @entity0 binding assay. Instead, a new PBP of poor binding capacity and anomalous molecular size (about 78 kilodaltons [kDa]) appeared in these cells. This corresponds to the molecular size of PBP 2a, the unique PBP that appears to be the biochemical correlate of resistance in clinical isolates of @entity2 -resistant @entity1 . Also, similar to the case of resistant clinical isolates, high-level @entity3 resistance was highly pH dependent in the laboratory mutants. We compared the patterns of radioactive peptides generated by partial proteolysis from the @entity0 -labeled PBP 2 of antibiotic-susceptible staphylococci and from the 78-kDa PBP 2a of a resistant clinical strain. Although the patterns were clearly different, seven of the eight characteristic peptides generated from PBP 2 of the susceptible strain were also detectable among the peptides released from PBP 2a. The results suggest that the 78-kDa PBP 2a of the resistant clinical strain evolved from PBP 2 of antibiotic-susceptible staphylococci and that in PBP 2a of the clinical isolate mutational changes have resulted in extensive alterations near the @entity3 binding site.

title: XXXX -specific resistant mutants of @entity1 .

answer: @entity3


abstract: Analysis of biopsy specimen obtained at autopsies performed in hospitals for @entity0 from 1981 to 1984 are presented, as well as the results of goal-directed studies of some @entity2 . It is noted that at adequate morphological and laboratory examinations the frequency of the diagnosed @entity2 is rather high revealing mainly combined @entity3 . The frequency of acute @entity7 is especially high, as it is found in 3/4 of the nonsurvivors. There are viral, bacterial, Mycoplasma-induced and other diseases among them. The data on frequency and specific morphological features of different etiologic groups of infection, as well as separate diseases are given. Acute @entity3 were less frequently diagnosed (in 9.8% of cases), @entity9 being predominant and appearing as a complication of different severe @entity1 . @entity4 occurred rather frequently, though its rate was gradually decreasing (from 11.1% to 5.3%). Infections with predominant intracanal generalization were rare. Meningococcemia, developing, as a rule, in the presence of generalized @entity8 , occurred in 2.2% of cases. @entity6 and @entity10 , more often bacterial ones, complicating @entity5 , were found in 4.5% of cases. Intrauterine @entity3 , in particular caused by Mycoplasmas and viruses (cytomegalic, herpetic and respiratory ones) were very often diagnosed. They were associated with the same type of placental damage. Chlamydiosis, evidently frequent, was almost unidentified. Bacterial intrauterine @entity3 including listeriosis were rare.

title: [Current aspects of infectious pathology in XXXX and fetuses].

answer: @entity0


abstract: Flowcytometer has been flourishing since the passed decade in our nation. Many general hospitals use it for routine tests. One of the main usage is immunophenotyping for @entity2 . Flowcytometric immunophenotyping (FCM-IM) facilitates accurate diagnosis in both @entity3 and @entity0 ( @entity0 ). It becomes an indispensable criteria in the diagnosis of @entity2 . It may also offer additional therapeutically relevant information. Typical patterns of immunophenotype in @entity3 and certain types of @entity0 are illustrated in figure 1 and figure 2. But variation or overlapping appears often. In order to reach a definitive diagnosis and to have a common interpretation between laboratory to laboratory the following items need not to be ignored: 1. Direct staining and multi-color or multi-parameter flow cytometric analysis is necessary. 2. The phenotype of abnormal cells should be determined on as pure a population as possible therefore @entity1 /SSC gating is critical for isolating the blast population (abnormal cells). @entity1 /SSC gating is much better than FSC/SSC gating especially when percentage of blast is low in the sample. Else, each @entity3 has its special @entity1 /SSC pattern. 3. The phenotype of this certain population should be described clearly but it is not necessary to count the percentage of each marker. 4. > 20% for positive threshold used in indirect staining method may be confused in multi-color direct staining method. 5. @entity4 diagnosed by FCM only should be in caution since the divergence of antigen/antibody, the lineage infidelity of antigen expression and the biological characteristics of the leukemic cells. Flowcytometer is not a cell counter. "It provides a pattern of information that must be interpreted by a knowledgeable professional in the context of the clinical situation".

title: [Flowcytometric-immunophenotyping for XXXX needs to be standardized].

answer: @entity3


abstract: BACKGROUND: The Internet is increasingly used for the recruitment of sex partners, potentially leading to increased risks for @entity2 ( @entity2 ). Less is known about the use of the Internet as a resource for STI education and prevention. GOAL: To evaluate the use of the Internet for sex-seeking and STI information purposes by clients of a large STI clinic. STUDY DESIGN: A 10-item survey was conducted among clients of the Denver Metro Health (STI) Clinic who visited the clinic for a new problem between September 2000 and May 2001. RESULTS: Among 4,741 clients surveyed, 2,159 (45.5%) had Internet access. Of these, 138 (6.4%) reported to have gone on-line with the specific purpose of finding a sex partner and 146 (6.8%) reported having sex with a partner they found over the Internet. Internet sex-seeking was more common among @entity0 who have sex with @entity0 (MSM; 77/269, or 28.6%) than among @entity0 who have sex with @entity0 (MSW; 52/1,176, or 4.4%; P < 0.0001) and higher among MSW than among @entity0 (9/714, or 1.3%; P < 0.001). The Internet was accessed by 604 @entity0 (28.0%) to find information on @entity2 . Of these, 65.1% did so for general STI information, 36.3% for information on @entity1 , 25.7% for @entity4 , 22.4% for information on chlamydia, 21.7% for information on HPV, 19.9% for information on @entity3 , 16.1% for information on syphilis, and 9.3% for other information. Of @entity0 seeking sex, 54.4% accessed the Internet for STI information, compared to 26.2% of @entity0 not seeking sex (P < 0.0001). CONCLUSIONS: Among STI clinic clients in Denver, nearly half have access to the Internet. Sex-seeking appears to be most prevalent among MSM. Internet use for STI information is common among those with Internet access and even more widespread among those who access the Internet to seek sex. Research is needed to develop and evaluate Internet-based STI-prevention interventions.

title: Risks and benefits of the internet for populations at risk for @entity2 ( XXXX ): results of an STI clinic survey.

answer: @entity2


abstract: BACKGROUND: The Internet is increasingly used for the recruitment of sex partners, potentially leading to increased risks for @entity2 ( @entity2 ). Less is known about the use of the Internet as a resource for STI education and prevention. GOAL: To evaluate the use of the Internet for sex-seeking and STI information purposes by clients of a large STI clinic. STUDY DESIGN: A 10-item survey was conducted among clients of the Denver Metro Health (STI) Clinic who visited the clinic for a new problem between September 2000 and May 2001. RESULTS: Among 4,741 clients surveyed, 2,159 (45.5%) had Internet access. Of these, 138 (6.4%) reported to have gone on-line with the specific purpose of finding a sex partner and 146 (6.8%) reported having sex with a partner they found over the Internet. Internet sex-seeking was more common among @entity0 who have sex with @entity0 (MSM; 77/269, or 28.6%) than among @entity0 who have sex with @entity0 (MSW; 52/1,176, or 4.4%; P < 0.0001) and higher among MSW than among @entity0 (9/714, or 1.3%; P < 0.001). The Internet was accessed by 604 @entity0 (28.0%) to find information on @entity2 . Of these, 65.1% did so for general STI information, 36.3% for information on @entity1 , 25.7% for @entity4 , 22.4% for information on chlamydia, 21.7% for information on HPV, 19.9% for information on @entity3 , 16.1% for information on syphilis, and 9.3% for other information. Of @entity0 seeking sex, 54.4% accessed the Internet for STI information, compared to 26.2% of @entity0 not seeking sex (P < 0.0001). CONCLUSIONS: Among STI clinic clients in Denver, nearly half have access to the Internet. Sex-seeking appears to be most prevalent among MSM. Internet use for STI information is common among those with Internet access and even more widespread among those who access the Internet to seek sex. Research is needed to develop and evaluate Internet-based STI-prevention interventions.

title: Risks and benefits of the internet for populations at risk for XXXX ( @entity2 ): results of an STI clinic survey.

answer: @entity2


abstract: AIM: To compare the diagnostic performance of chest sonography, MRI angiography and ventilation/perfusion intigraphy in @entity5 ( @entity5 ). METHOD: In a prospective clinical study, 55 @entity0 (41 @entity0 , 14 @entity0 , age 23 - 91 years) with clinical signs of @entity5 were investigated within 48 hours of the onset of symptoms. The final diagnosis was made by MRI angiography (reference method). RESULTS: @entity5 was diagnosed in a total of 36 @entity0 . Chest sonography revealed rounded or wedge-shaped @entity1 in 30 @entity0 . On ventilation/perfusion (V/P) scintigraphy, 41 @entity0 had positive V/P scans, but only 23 were of high probability. Chest ultrasound had a positive predictive value of 97 % to diagnose @entity5 . The sensitivity, specificity, the negative predictive value and accuracy were 81 %, 84 %, 84 % and 82 %, respectively. As 18 @entity0 had inconclusive scans, the diagnostic performance of ventilation/perfusion scintigraphy was poor. The positive predictive value, sensitivity and specificity were 58 %, 42 % and 91 %, respectively. @entity0 in whom @entity5 was excluded mainly suffered from @entity4 , @entity3 or @entity2 . CONCLUSION: A negative sonographic study cannot rule out @entity5 with certainty. However, a chest sonography is of acceptable diagnostic value in @entity0 with suspected @entity5 and may be used as an adjunct or guide to more established methods.

title: Chest sonography in the diagnosis of XXXX : a comparison with MRI angiography and ventilation perfusion scintigraphy.

answer: @entity5


abstract: BACKGROUND AND AIM: It has been reported that plasma @entity7 ( @entity10 ) levels in type 1 @entity1 (T1DM) @entity0 without renal involvement are higher, similar to or lower than those in healthy controls. METHODS AND RESULTS: We measured plasma @entity10 in 60 controls, 79 type 1 @entity1 (23 with @entity5 , 22 with @entity2 ) and 73 non-diabetic relatives of 30 probands. The female controls had lower levels than their male counterparts: geometric mean 10.5 vs 13.6 mumol/L, p < 0.001. Among the controls, smokers (n = 20) and ex-smokers (n = 12) had higher @entity10 levels than non-smokers (n = 28): 13.2 and 13.2 vs 10.9 mumol/L, p < 0.01. Among the @entity1 , high plasma @entity10 levels were associated with male gender: 11.9 vs 9.1 mumol/L in @entity0 , p < 0.01. The @entity0 without complications had higher plasma @entity3 and hemoglobin A1c (HbA1c) levels (p < 0.001), and lower plasma @entity10 (9.2 mumol/L vs 12.2, p < 0.01) and @entity4 levels (p < 0.05) than the controls. The @entity0 with @entity2 and higher levels of @entity10 (13.0 mumol/L vs 9.0, p < 0.05), and different levels of @entity6 (p < 0.01), @entity4 (p < 0.01), @entity8 (p < 0.05), and urinary albumin (p < 0.001) than those with @entity5 . There was no difference in @entity10 levels between the @entity0 ' relatives and the controls: 11.9 mumol/L in siblings vs 11.6 mumol/L, 13.5 mumol/L in parents vs 12.1 mumol/L. In the control group, plasma @entity10 levels were associated with age, gender and smoking; among the @entity1 , they correlated with age, gender, smoking, and plasma @entity6 and lipoprotein (a) levels. CONCLUSIONS: 1) male gender and smoking are associated with high @entity10 levels in healthy @entity0 ; 2) plasma @entity10 levels are lower in T1DM @entity0 than in healthy @entity0 (glomerular hyperfiltration and accelerated hepatic transsulfuration?); 3) high @entity10 levels are associated with @entity9 and plasma @entity6 levels; and 4) non-diabetic first-degree relatives of type 1 @entity1 have normal plasma @entity10 concentrations.

title: Blood levels of total @entity7 in @entity0 with type 1 @entity1 (with no complications, @entity9 and/or XXXX ) and in their non-diabetic relatives.

answer: @entity5


abstract: BACKGROUND AND AIM: It has been reported that plasma @entity7 ( @entity10 ) levels in type 1 @entity1 (T1DM) @entity0 without renal involvement are higher, similar to or lower than those in healthy controls. METHODS AND RESULTS: We measured plasma @entity10 in 60 controls, 79 type 1 @entity1 (23 with @entity5 , 22 with @entity2 ) and 73 non-diabetic relatives of 30 probands. The female controls had lower levels than their male counterparts: geometric mean 10.5 vs 13.6 mumol/L, p < 0.001. Among the controls, smokers (n = 20) and ex-smokers (n = 12) had higher @entity10 levels than non-smokers (n = 28): 13.2 and 13.2 vs 10.9 mumol/L, p < 0.01. Among the @entity1 , high plasma @entity10 levels were associated with male gender: 11.9 vs 9.1 mumol/L in @entity0 , p < 0.01. The @entity0 without complications had higher plasma @entity3 and hemoglobin A1c (HbA1c) levels (p < 0.001), and lower plasma @entity10 (9.2 mumol/L vs 12.2, p < 0.01) and @entity4 levels (p < 0.05) than the controls. The @entity0 with @entity2 and higher levels of @entity10 (13.0 mumol/L vs 9.0, p < 0.05), and different levels of @entity6 (p < 0.01), @entity4 (p < 0.01), @entity8 (p < 0.05), and urinary albumin (p < 0.001) than those with @entity5 . There was no difference in @entity10 levels between the @entity0 ' relatives and the controls: 11.9 mumol/L in siblings vs 11.6 mumol/L, 13.5 mumol/L in parents vs 12.1 mumol/L. In the control group, plasma @entity10 levels were associated with age, gender and smoking; among the @entity1 , they correlated with age, gender, smoking, and plasma @entity6 and lipoprotein (a) levels. CONCLUSIONS: 1) male gender and smoking are associated with high @entity10 levels in healthy @entity0 ; 2) plasma @entity10 levels are lower in T1DM @entity0 than in healthy @entity0 (glomerular hyperfiltration and accelerated hepatic transsulfuration?); 3) high @entity10 levels are associated with @entity9 and plasma @entity6 levels; and 4) non-diabetic first-degree relatives of type 1 @entity1 have normal plasma @entity10 concentrations.

title: Blood levels of total @entity7 in @entity0 with type 1 XXXX (with no complications, @entity9 and/or @entity5 ) and in their non-diabetic relatives.

answer: @entity1


abstract: BACKGROUND AND AIM: It has been reported that plasma @entity7 ( @entity10 ) levels in type 1 @entity1 (T1DM) @entity0 without renal involvement are higher, similar to or lower than those in healthy controls. METHODS AND RESULTS: We measured plasma @entity10 in 60 controls, 79 type 1 @entity1 (23 with @entity5 , 22 with @entity2 ) and 73 non-diabetic relatives of 30 probands. The female controls had lower levels than their male counterparts: geometric mean 10.5 vs 13.6 mumol/L, p < 0.001. Among the controls, smokers (n = 20) and ex-smokers (n = 12) had higher @entity10 levels than non-smokers (n = 28): 13.2 and 13.2 vs 10.9 mumol/L, p < 0.01. Among the @entity1 , high plasma @entity10 levels were associated with male gender: 11.9 vs 9.1 mumol/L in @entity0 , p < 0.01. The @entity0 without complications had higher plasma @entity3 and hemoglobin A1c (HbA1c) levels (p < 0.001), and lower plasma @entity10 (9.2 mumol/L vs 12.2, p < 0.01) and @entity4 levels (p < 0.05) than the controls. The @entity0 with @entity2 and higher levels of @entity10 (13.0 mumol/L vs 9.0, p < 0.05), and different levels of @entity6 (p < 0.01), @entity4 (p < 0.01), @entity8 (p < 0.05), and urinary albumin (p < 0.001) than those with @entity5 . There was no difference in @entity10 levels between the @entity0 ' relatives and the controls: 11.9 mumol/L in siblings vs 11.6 mumol/L, 13.5 mumol/L in parents vs 12.1 mumol/L. In the control group, plasma @entity10 levels were associated with age, gender and smoking; among the @entity1 , they correlated with age, gender, smoking, and plasma @entity6 and lipoprotein (a) levels. CONCLUSIONS: 1) male gender and smoking are associated with high @entity10 levels in healthy @entity0 ; 2) plasma @entity10 levels are lower in T1DM @entity0 than in healthy @entity0 (glomerular hyperfiltration and accelerated hepatic transsulfuration?); 3) high @entity10 levels are associated with @entity9 and plasma @entity6 levels; and 4) non-diabetic first-degree relatives of type 1 @entity1 have normal plasma @entity10 concentrations.

title: Blood levels of total XXXX in @entity0 with type 1 @entity1 (with no complications, @entity9 and/or @entity5 ) and in their non-diabetic relatives.

answer: @entity7


abstract: BACKGROUND AND AIM: It has been reported that plasma @entity7 ( @entity10 ) levels in type 1 @entity1 (T1DM) @entity0 without renal involvement are higher, similar to or lower than those in healthy controls. METHODS AND RESULTS: We measured plasma @entity10 in 60 controls, 79 type 1 @entity1 (23 with @entity5 , 22 with @entity2 ) and 73 non-diabetic relatives of 30 probands. The female controls had lower levels than their male counterparts: geometric mean 10.5 vs 13.6 mumol/L, p < 0.001. Among the controls, smokers (n = 20) and ex-smokers (n = 12) had higher @entity10 levels than non-smokers (n = 28): 13.2 and 13.2 vs 10.9 mumol/L, p < 0.01. Among the @entity1 , high plasma @entity10 levels were associated with male gender: 11.9 vs 9.1 mumol/L in @entity0 , p < 0.01. The @entity0 without complications had higher plasma @entity3 and hemoglobin A1c (HbA1c) levels (p < 0.001), and lower plasma @entity10 (9.2 mumol/L vs 12.2, p < 0.01) and @entity4 levels (p < 0.05) than the controls. The @entity0 with @entity2 and higher levels of @entity10 (13.0 mumol/L vs 9.0, p < 0.05), and different levels of @entity6 (p < 0.01), @entity4 (p < 0.01), @entity8 (p < 0.05), and urinary albumin (p < 0.001) than those with @entity5 . There was no difference in @entity10 levels between the @entity0 ' relatives and the controls: 11.9 mumol/L in siblings vs 11.6 mumol/L, 13.5 mumol/L in parents vs 12.1 mumol/L. In the control group, plasma @entity10 levels were associated with age, gender and smoking; among the @entity1 , they correlated with age, gender, smoking, and plasma @entity6 and lipoprotein (a) levels. CONCLUSIONS: 1) male gender and smoking are associated with high @entity10 levels in healthy @entity0 ; 2) plasma @entity10 levels are lower in T1DM @entity0 than in healthy @entity0 (glomerular hyperfiltration and accelerated hepatic transsulfuration?); 3) high @entity10 levels are associated with @entity9 and plasma @entity6 levels; and 4) non-diabetic first-degree relatives of type 1 @entity1 have normal plasma @entity10 concentrations.

title: Blood levels of total @entity7 in @entity0 with type 1 @entity1 (with no complications, XXXX and/or @entity5 ) and in their non-diabetic relatives.

answer: @entity9


abstract: BACKGROUND AND AIM: It has been reported that plasma @entity7 ( @entity10 ) levels in type 1 @entity1 (T1DM) @entity0 without renal involvement are higher, similar to or lower than those in healthy controls. METHODS AND RESULTS: We measured plasma @entity10 in 60 controls, 79 type 1 @entity1 (23 with @entity5 , 22 with @entity2 ) and 73 non-diabetic relatives of 30 probands. The female controls had lower levels than their male counterparts: geometric mean 10.5 vs 13.6 mumol/L, p < 0.001. Among the controls, smokers (n = 20) and ex-smokers (n = 12) had higher @entity10 levels than non-smokers (n = 28): 13.2 and 13.2 vs 10.9 mumol/L, p < 0.01. Among the @entity1 , high plasma @entity10 levels were associated with male gender: 11.9 vs 9.1 mumol/L in @entity0 , p < 0.01. The @entity0 without complications had higher plasma @entity3 and hemoglobin A1c (HbA1c) levels (p < 0.001), and lower plasma @entity10 (9.2 mumol/L vs 12.2, p < 0.01) and @entity4 levels (p < 0.05) than the controls. The @entity0 with @entity2 and higher levels of @entity10 (13.0 mumol/L vs 9.0, p < 0.05), and different levels of @entity6 (p < 0.01), @entity4 (p < 0.01), @entity8 (p < 0.05), and urinary albumin (p < 0.001) than those with @entity5 . There was no difference in @entity10 levels between the @entity0 ' relatives and the controls: 11.9 mumol/L in siblings vs 11.6 mumol/L, 13.5 mumol/L in parents vs 12.1 mumol/L. In the control group, plasma @entity10 levels were associated with age, gender and smoking; among the @entity1 , they correlated with age, gender, smoking, and plasma @entity6 and lipoprotein (a) levels. CONCLUSIONS: 1) male gender and smoking are associated with high @entity10 levels in healthy @entity0 ; 2) plasma @entity10 levels are lower in T1DM @entity0 than in healthy @entity0 (glomerular hyperfiltration and accelerated hepatic transsulfuration?); 3) high @entity10 levels are associated with @entity9 and plasma @entity6 levels; and 4) non-diabetic first-degree relatives of type 1 @entity1 have normal plasma @entity10 concentrations.

title: Blood levels of total @entity7 in XXXX with type 1 @entity1 (with no complications, @entity9 and/or @entity5 ) and in their non-diabetic relatives.

answer: @entity0


abstract: @entity4 remains an actual medical and social problem for Bulgaria as an endemic region. Because of the lackage of medicines with satisfactory therapeutic effect the surgical treatment is still the treatment of primary importance. AIM: The aim of this study was too check the correctness of the following hypothesis: "Radical surgical procedures on @entity4 have lower rates of morbidity and mortality compared to conservative ones". MATERIAL AND METHODS: In order to achieve the above mentioned aim we analysed the results of 361 @entity0 with @entity4 (267 (74%) of whom retrospectively and 94 (26%) prospectively), treated at the Clinic of General, Liver and Pancreatic Surgery during the period 1st, Jan., 1985-1st, Jan., 2001. The @entity0 were divided in two main groups: 102 (28.25%) of them received radical surgical procedures and 250 (69.25%)--conservative ones. Nine of the @entity0 (2.50%) had @entity1 and received surgical procedures of both types. That's why the results of those @entity0 did not correspond to the aim of the study and they were not included in it. The analysis consisted of a comparison between the two main groups according to several criteria: sex, age, location and average size of the cysts, @entity3 , reoperations, mean postoperative stay at hospital and mortality rate. RESULTS: There was a prevalence of the female in the ratio male/female in the group of @entity0 who received a radical procedure. The location of @entity2 was found to be more frequent. In the group of radical surgical operations the postoperative morbidity and mortality rates were lower and the postoperative stay at hospital was shorter, compared to the group of conservative procedures. CONCLUSION: Radical surgical procedures showed better postoperative results. But those procedures had to be performed only on @entity0 who had certain indications and according to criteria described in surgical literature. The proper surgical equipment and well experienced surgical team were the other important conditions for good outcome.

title: [ XXXX : radical or conservative surgical treatment].

answer: @entity2


abstract: This report is an analysis of the morbidity in the bladder and bowel observed in a randomized trial of d(15)+Be neutrons versus megavoltage photons in the treatment of @entity1 . Acute reactions in the bladder and bowel were significantly worse after photon therapy. Of the @entity0 treated with photons 45.7% had severe reactions in the bladder compared with 10.6% after neutron therapy (p less than 0.001). Severe acute bowel reactions were observed in 8.5% of the @entity0 after photon therapy compared with 3.8% after neutron therapy (p less than 0.05). Late reactions were significantly worse after neutrons. Severe late reactions in the bladder were seen in 58.5% of @entity0 after neutron therapy and in 40.5% after photon therapy (p less than 0.05). In the bowel they were observed in 53.3% of @entity0 after neutron therapy compared with 8% after photon therapy (p less than 0.0001). The disparity in the degree of early and late complications makes assessment of RBE values difficult. It is estimated that for bladder morbidity the RBE value, for photon dose fractions of 2.75 Gy, is less than 3.3 for early reactions and equal to 3.4 for late effects. The respective RBE values for early and late effects in the bowel are less than 3.4 and 3.8.

title: An analysis of the radiation related morbidity observed in a randomized trial of neutron therapy for XXXX .

answer: @entity1


abstract: Extensive clinical and clinical chemical information was collected from 1002 consecutive @entity1 @entity0 . Initial selection of variables based on Chi 2-tests or Mann-Whitney U-test allowed the removal of 64 of the 107 variables originally collected. A further selection of variables was carried out using a modified version of Bayes' rule thus reducing the number of variables from 43 to 22. Of the 982 @entity0 with a final diagnosis 743 @entity0 (76%) could be classified correctly into one of 13 diagnostic categories. The Bayes' rule was also applied to a test group of a further 110 @entity1 @entity0 and found to perform equally well: of 108 @entity0 with a final diagnosis 81 (75%) were correctly classified. A comparison between the clinician's diagnosis and the computer-aided diagnosis according to Bayes' rule demonstrated agreement with regard to one of the 13 diagnostic alternatives in 734 @entity0 (75%), of whom 81 @entity0 were wrongly diagnosed. In the test group agreement upon diagnosis was found in 80 @entity0 (74%). By plausibly combining the computer-aided and the clinician's preliminary diagnoses, more correct classifications were obtained than with either method alone. Many diagnostic modalities such as ultrasound examination, CT-scan, and direct cholangiography are at hand today for the differential diagnosis of @entity1 . Computer-aided diagnosis using Bayes' rule has proved a reliable tool for the clinician and can be used in the planning of a diagnostic strategy for the individual @entity1 @entity0 .

title: Computer diagnosis in XXXX . Bayes' rule founded on 1002 consecutive cases.

answer: @entity1


abstract: A great number of investigators have, independently, shown that @entity1 blood flow is affected by a hyperthermic treatment to a larger extent than normal tissue blood flow. While the majority of the studies on experimental @entity1 show a decrease and even a lapse in blood flow within the microcirculation during or after @entity3 , the data on @entity0 @entity1 are less conclusive. Some of the investigators do not find a decrease in circulation, while others do. Obviously, this is an important field of investigation in the clinical application of @entity3 because a shut down of the circulation would not only facilitate @entity1 heating (by reducing venous outflow, this reducing the 'heat clearance' from the @entity1 ), but would also facilitate @entity1 cell destruction. The same holds for alterations that occur subsequently to the circulatory changes, like a heat-induced decrease of tissue @entity5 and pH. If the frequently reported circulatory collapse of the @entity1 circulation could selectively be stimulated by, e.g. acidification or by vasoactive agents, hyperthermic treatment of @entity0 would possibly be greatly facilitated and intensified. In hyperthermic @entity1 therapy a number of complex processes and interactions takes place, especially when the treatment is performed in combination with radiation therapy. One of them represents the group of processes related to the random probability of cell sterilization of individual @entity1 cells resulting in exponential survival curves which are typically evaluated with e.g. cell survival assays. This aspect has not been the issue of this paper. The other group of processes deals with the heat-induced changes in the micro-physiology of @entity1 and normal tissues which, as discussed before, may not only enhance the exponential cell kill, but which may also culminate in @entity4 with the ensuing @entity2 of the @entity1 tissue in the areas affected. If this takes place, a process of bulk killing of @entity1 cells results, rather than the random type of cell sterilization. At present it is not clear to what extent the various separate mechanisms contribute to the total effect of @entity1 control. With all these considerations in mind, one should be aware of the fact that effects, secondary to heat-induced @entity4 alone will never be efficient enough to eliminate all @entity1 cells, even though a heat reservoir is created. This is so because some malignant cells will inevitably have already infiltrated normal, surrounding structures and will therefore not be affected by changes in the @entity1 vascular bed.(ABSTRACT TRUNCATED AT 400 WORDS)

title: Tumour microcirculation as a target for XXXX .

answer: @entity3


abstract: BACKGROUND: Despite the considerable physical, emotional and social change that occurs during emerging adulthood, there is little research that examines the association between having a chronic health condition and @entity0 during this developmental period. The aims of this study were to examine the sex-specific prevalence of @entity0 in an epidemiological sample of emerging adults aged 15-30 years with and without chronic health conditions; quantify the association between chronic health conditions and @entity0 , adjusting for sociodemographic and health factors; and, examine potential moderating and mediating effects of sex, level of disability and @entity2 . METHOD: Data come from the Canadian Community Health Survey-Mental Health. Respondents were 15-30 years of age (n = 5947) and self-reported whether they had a chronic health condition. Chronic health conditions were classified as: respiratory, musculoskeletal/connective tissue, cardiovascular, neurological and endocrine/digestive. The World Health Organization Composite International Diagnostic Interview 3.0 was used to assess the presence of @entity0 ( @entity4 , suicidal behaviour, @entity3 and generalised @entity1 ). RESULTS: Lifetime prevalence of @entity0 was significantly higher for individuals with chronic health conditions compared with healthy controls. Substantial heterogeneity in the prevalence of @entity0 was found in males, but not in females. @entity5 models adjusting for several sociodemographic and health factors showed that the individuals with chronic health conditions were at elevated risk for @entity0 . There was no evidence that the level of disability or @entity2 moderated the associations between chronic health conditions and @entity0 . Sex was found to moderate the association between musculoskeletal/connective tissue conditions and @entity3 (b = 1.71, p = 0.002). Exploratory analyses suggest that the levels of disability and @entity2 mediate the association between chronic health conditions and @entity0 . CONCLUSIONS: Physical and mental comorbidity is prevalent among emerging adults and this relationship is not augmented, but may be mediated, by the level of disability or @entity2 . Findings point to the integration and coordination of public sectors - health, education and social services - to facilitate the prevention and reduction of @entity0 among emerging adults with chronic health conditions.

title: Major @entity4 , suicidal behaviour, XXXX , and generalised @entity1 among emerging adults with and without chronic health conditions.

answer: @entity3


abstract: BACKGROUND: Despite the considerable physical, emotional and social change that occurs during emerging adulthood, there is little research that examines the association between having a chronic health condition and @entity0 during this developmental period. The aims of this study were to examine the sex-specific prevalence of @entity0 in an epidemiological sample of emerging adults aged 15-30 years with and without chronic health conditions; quantify the association between chronic health conditions and @entity0 , adjusting for sociodemographic and health factors; and, examine potential moderating and mediating effects of sex, level of disability and @entity2 . METHOD: Data come from the Canadian Community Health Survey-Mental Health. Respondents were 15-30 years of age (n = 5947) and self-reported whether they had a chronic health condition. Chronic health conditions were classified as: respiratory, musculoskeletal/connective tissue, cardiovascular, neurological and endocrine/digestive. The World Health Organization Composite International Diagnostic Interview 3.0 was used to assess the presence of @entity0 ( @entity4 , suicidal behaviour, @entity3 and generalised @entity1 ). RESULTS: Lifetime prevalence of @entity0 was significantly higher for individuals with chronic health conditions compared with healthy controls. Substantial heterogeneity in the prevalence of @entity0 was found in males, but not in females. @entity5 models adjusting for several sociodemographic and health factors showed that the individuals with chronic health conditions were at elevated risk for @entity0 . There was no evidence that the level of disability or @entity2 moderated the associations between chronic health conditions and @entity0 . Sex was found to moderate the association between musculoskeletal/connective tissue conditions and @entity3 (b = 1.71, p = 0.002). Exploratory analyses suggest that the levels of disability and @entity2 mediate the association between chronic health conditions and @entity0 . CONCLUSIONS: Physical and mental comorbidity is prevalent among emerging adults and this relationship is not augmented, but may be mediated, by the level of disability or @entity2 . Findings point to the integration and coordination of public sectors - health, education and social services - to facilitate the prevention and reduction of @entity0 among emerging adults with chronic health conditions.

title: Major XXXX , suicidal behaviour, @entity3 , and generalised @entity1 among emerging adults with and without chronic health conditions.

answer: @entity4


abstract: BACKGROUND: Despite the considerable physical, emotional and social change that occurs during emerging adulthood, there is little research that examines the association between having a chronic health condition and @entity0 during this developmental period. The aims of this study were to examine the sex-specific prevalence of @entity0 in an epidemiological sample of emerging adults aged 15-30 years with and without chronic health conditions; quantify the association between chronic health conditions and @entity0 , adjusting for sociodemographic and health factors; and, examine potential moderating and mediating effects of sex, level of disability and @entity2 . METHOD: Data come from the Canadian Community Health Survey-Mental Health. Respondents were 15-30 years of age (n = 5947) and self-reported whether they had a chronic health condition. Chronic health conditions were classified as: respiratory, musculoskeletal/connective tissue, cardiovascular, neurological and endocrine/digestive. The World Health Organization Composite International Diagnostic Interview 3.0 was used to assess the presence of @entity0 ( @entity4 , suicidal behaviour, @entity3 and generalised @entity1 ). RESULTS: Lifetime prevalence of @entity0 was significantly higher for individuals with chronic health conditions compared with healthy controls. Substantial heterogeneity in the prevalence of @entity0 was found in males, but not in females. @entity5 models adjusting for several sociodemographic and health factors showed that the individuals with chronic health conditions were at elevated risk for @entity0 . There was no evidence that the level of disability or @entity2 moderated the associations between chronic health conditions and @entity0 . Sex was found to moderate the association between musculoskeletal/connective tissue conditions and @entity3 (b = 1.71, p = 0.002). Exploratory analyses suggest that the levels of disability and @entity2 mediate the association between chronic health conditions and @entity0 . CONCLUSIONS: Physical and mental comorbidity is prevalent among emerging adults and this relationship is not augmented, but may be mediated, by the level of disability or @entity2 . Findings point to the integration and coordination of public sectors - health, education and social services - to facilitate the prevention and reduction of @entity0 among emerging adults with chronic health conditions.

title: Major @entity4 , suicidal behaviour, @entity3 , and generalised XXXX among emerging adults with and without chronic health conditions.

answer: @entity1


abstract: PURPOSE: The aim of this study is to assess how @entity1 ( @entity1 ) is used worldwide to test ovarian reserve and guide @entity0 ( @entity0 ) cycle management. METHODS: An internet-based survey was sent electronically to registered @entity0 providers within the @entity0 -Worldwide.com network. This survey consisted of nine questions which assessed the clinics' use of @entity1 . The questionnaire was completed online through the @entity0 -Worldwide.com website, and quality assurance tools were used to verify that only one survey was completed per clinical @entity0 center. Results are reported as the proportion of @entity0 cycles represented by a particular answer choice. RESULTS: Survey responses were completed from 796 globally distributed @entity0 clinics, representing 593,200 @entity0 cycles worldwide. Sixty percent of the respondent- @entity0 cycles reported to use @entity1 as a first line test, and 54 % reported it as the best test for evaluating ovarian reserve. Eighty-nine percent reported that @entity1 results were extremely relevant or relevant to clinical practice. However in contrast, for predicting live birth rate, 81 % reported age as the best predictor. CONCLUSIONS: @entity1 is currently considered a first line test for evaluating ovarian reserve and is considered relevant to clinical practice by the majority of @entity0 providers.

title: Use of XXXX for testing ovarian reserve: a survey of 796 infertility clinics worldwide.

answer: @entity1


abstract: BACKGROUND: Metastatic @entity0 is a major cause of @entity5 among @entity1 worldwide; therefore efficient therapeutic strategies are extremely needed. In this work we have developed a gene therapy- and bacteria-based combined neoadjuvant approach and evaluated its antitumor effect in a clinically relevant animal model of metastatic @entity0 . METHODS: 2*10(8) particles of a @entity7 vector expressing interleukin-12 ( @entity8 -IL-12) and/or 2*10(7) units of an aroC (-) @entity6 (LVR01) were injected into 4T1 @entity3 nodules orthotopically implanted in @entity4 . @entity3 were surgically resected and long-term survival was determined. IL-12 and interferon-y were quantified by Enzyme-Linked ImmunoSorbent Assay, bacteria was visualized by inmunohistochemistry and the number of lung @entity2 was calculated with a clonogenic assay. RESULTS: @entity8 -IL-12 and LVR01 timely inoculated and followed by surgical resection of @entity3 succeeded in complete inhibition of lethal lung @entity2 and long-term survival in 90% of treated @entity4 . The combined therapy was markedly synergistic compared to each treatment alone, since @entity8 -IL-12 monotherapy showed a potent antiangiogenic effect, being able to inhibit @entity3 growth and extend survival, but could not prevent establishment of distant @entity2 and @entity5 of @entity3 -excised animals. On the other hand, LVR01 alone also showed a significant, although limited, antitumor potential, despite its ability to invade @entity0 cells and induce granulocyte recruitment. The efficacy of the combined therapy depended on the order in which both factors were administered; inasmuch the therapeutic effect was only observed when @entity8 -IL-12 was administered previous to LVR01, whereas administration of LVR01 before @entity8 -IL-12 had negligible antitumor activity. Moreover, pre-treatment with LVR01 seemed to suppress @entity8 -IL-12 antiangiogenic effects associated to lower IL-12 expression in this group. Re-challenged @entity4 were unable to reject a second 4T1 @entity3 ; however 100% of them could be totally cured by applying the same neoadjuvant combined regimen. To our knowledge, these are the most encouraging results obtained to date in a post-operatory setting using the highly aggressive 4T1 animal model. CONCLUSIONS: @entity8 -IL-12-based gene therapy combined with @entity6 LVR01 neoadjuvant administration has a synergic antitumor effect and may be a promising therapeutic option to prevent and/or eradicate pre-operatory @entity2 in locally advanced @entity0 .

title: Neoadjuvant administration of XXXX expressing interleukin-12 combined with attenuated @entity6 eradicates @entity0 @entity2 and achieves long-term survival in immunocompetent @entity4 .

answer: @entity7


abstract: BACKGROUND: Metastatic @entity0 is a major cause of @entity5 among @entity1 worldwide; therefore efficient therapeutic strategies are extremely needed. In this work we have developed a gene therapy- and bacteria-based combined neoadjuvant approach and evaluated its antitumor effect in a clinically relevant animal model of metastatic @entity0 . METHODS: 2*10(8) particles of a @entity7 vector expressing interleukin-12 ( @entity8 -IL-12) and/or 2*10(7) units of an aroC (-) @entity6 (LVR01) were injected into 4T1 @entity3 nodules orthotopically implanted in @entity4 . @entity3 were surgically resected and long-term survival was determined. IL-12 and interferon-y were quantified by Enzyme-Linked ImmunoSorbent Assay, bacteria was visualized by inmunohistochemistry and the number of lung @entity2 was calculated with a clonogenic assay. RESULTS: @entity8 -IL-12 and LVR01 timely inoculated and followed by surgical resection of @entity3 succeeded in complete inhibition of lethal lung @entity2 and long-term survival in 90% of treated @entity4 . The combined therapy was markedly synergistic compared to each treatment alone, since @entity8 -IL-12 monotherapy showed a potent antiangiogenic effect, being able to inhibit @entity3 growth and extend survival, but could not prevent establishment of distant @entity2 and @entity5 of @entity3 -excised animals. On the other hand, LVR01 alone also showed a significant, although limited, antitumor potential, despite its ability to invade @entity0 cells and induce granulocyte recruitment. The efficacy of the combined therapy depended on the order in which both factors were administered; inasmuch the therapeutic effect was only observed when @entity8 -IL-12 was administered previous to LVR01, whereas administration of LVR01 before @entity8 -IL-12 had negligible antitumor activity. Moreover, pre-treatment with LVR01 seemed to suppress @entity8 -IL-12 antiangiogenic effects associated to lower IL-12 expression in this group. Re-challenged @entity4 were unable to reject a second 4T1 @entity3 ; however 100% of them could be totally cured by applying the same neoadjuvant combined regimen. To our knowledge, these are the most encouraging results obtained to date in a post-operatory setting using the highly aggressive 4T1 animal model. CONCLUSIONS: @entity8 -IL-12-based gene therapy combined with @entity6 LVR01 neoadjuvant administration has a synergic antitumor effect and may be a promising therapeutic option to prevent and/or eradicate pre-operatory @entity2 in locally advanced @entity0 .

title: Neoadjuvant administration of @entity7 expressing interleukin-12 combined with attenuated @entity6 eradicates @entity0 @entity2 and achieves long-term survival in immunocompetent XXXX .

answer: @entity4


abstract: BACKGROUND: Metastatic @entity0 is a major cause of @entity5 among @entity1 worldwide; therefore efficient therapeutic strategies are extremely needed. In this work we have developed a gene therapy- and bacteria-based combined neoadjuvant approach and evaluated its antitumor effect in a clinically relevant animal model of metastatic @entity0 . METHODS: 2*10(8) particles of a @entity7 vector expressing interleukin-12 ( @entity8 -IL-12) and/or 2*10(7) units of an aroC (-) @entity6 (LVR01) were injected into 4T1 @entity3 nodules orthotopically implanted in @entity4 . @entity3 were surgically resected and long-term survival was determined. IL-12 and interferon-y were quantified by Enzyme-Linked ImmunoSorbent Assay, bacteria was visualized by inmunohistochemistry and the number of lung @entity2 was calculated with a clonogenic assay. RESULTS: @entity8 -IL-12 and LVR01 timely inoculated and followed by surgical resection of @entity3 succeeded in complete inhibition of lethal lung @entity2 and long-term survival in 90% of treated @entity4 . The combined therapy was markedly synergistic compared to each treatment alone, since @entity8 -IL-12 monotherapy showed a potent antiangiogenic effect, being able to inhibit @entity3 growth and extend survival, but could not prevent establishment of distant @entity2 and @entity5 of @entity3 -excised animals. On the other hand, LVR01 alone also showed a significant, although limited, antitumor potential, despite its ability to invade @entity0 cells and induce granulocyte recruitment. The efficacy of the combined therapy depended on the order in which both factors were administered; inasmuch the therapeutic effect was only observed when @entity8 -IL-12 was administered previous to LVR01, whereas administration of LVR01 before @entity8 -IL-12 had negligible antitumor activity. Moreover, pre-treatment with LVR01 seemed to suppress @entity8 -IL-12 antiangiogenic effects associated to lower IL-12 expression in this group. Re-challenged @entity4 were unable to reject a second 4T1 @entity3 ; however 100% of them could be totally cured by applying the same neoadjuvant combined regimen. To our knowledge, these are the most encouraging results obtained to date in a post-operatory setting using the highly aggressive 4T1 animal model. CONCLUSIONS: @entity8 -IL-12-based gene therapy combined with @entity6 LVR01 neoadjuvant administration has a synergic antitumor effect and may be a promising therapeutic option to prevent and/or eradicate pre-operatory @entity2 in locally advanced @entity0 .

title: Neoadjuvant administration of @entity7 expressing interleukin-12 combined with attenuated @entity6 eradicates XXXX @entity2 and achieves long-term survival in immunocompetent @entity4 .

answer: @entity0


abstract: BACKGROUND: Metastatic @entity0 is a major cause of @entity5 among @entity1 worldwide; therefore efficient therapeutic strategies are extremely needed. In this work we have developed a gene therapy- and bacteria-based combined neoadjuvant approach and evaluated its antitumor effect in a clinically relevant animal model of metastatic @entity0 . METHODS: 2*10(8) particles of a @entity7 vector expressing interleukin-12 ( @entity8 -IL-12) and/or 2*10(7) units of an aroC (-) @entity6 (LVR01) were injected into 4T1 @entity3 nodules orthotopically implanted in @entity4 . @entity3 were surgically resected and long-term survival was determined. IL-12 and interferon-y were quantified by Enzyme-Linked ImmunoSorbent Assay, bacteria was visualized by inmunohistochemistry and the number of lung @entity2 was calculated with a clonogenic assay. RESULTS: @entity8 -IL-12 and LVR01 timely inoculated and followed by surgical resection of @entity3 succeeded in complete inhibition of lethal lung @entity2 and long-term survival in 90% of treated @entity4 . The combined therapy was markedly synergistic compared to each treatment alone, since @entity8 -IL-12 monotherapy showed a potent antiangiogenic effect, being able to inhibit @entity3 growth and extend survival, but could not prevent establishment of distant @entity2 and @entity5 of @entity3 -excised animals. On the other hand, LVR01 alone also showed a significant, although limited, antitumor potential, despite its ability to invade @entity0 cells and induce granulocyte recruitment. The efficacy of the combined therapy depended on the order in which both factors were administered; inasmuch the therapeutic effect was only observed when @entity8 -IL-12 was administered previous to LVR01, whereas administration of LVR01 before @entity8 -IL-12 had negligible antitumor activity. Moreover, pre-treatment with LVR01 seemed to suppress @entity8 -IL-12 antiangiogenic effects associated to lower IL-12 expression in this group. Re-challenged @entity4 were unable to reject a second 4T1 @entity3 ; however 100% of them could be totally cured by applying the same neoadjuvant combined regimen. To our knowledge, these are the most encouraging results obtained to date in a post-operatory setting using the highly aggressive 4T1 animal model. CONCLUSIONS: @entity8 -IL-12-based gene therapy combined with @entity6 LVR01 neoadjuvant administration has a synergic antitumor effect and may be a promising therapeutic option to prevent and/or eradicate pre-operatory @entity2 in locally advanced @entity0 .

title: Neoadjuvant administration of @entity7 expressing interleukin-12 combined with attenuated @entity6 eradicates @entity0 XXXX and achieves long-term survival in immunocompetent @entity4 .

answer: @entity2


abstract: BACKGROUND: Metastatic @entity0 is a major cause of @entity5 among @entity1 worldwide; therefore efficient therapeutic strategies are extremely needed. In this work we have developed a gene therapy- and bacteria-based combined neoadjuvant approach and evaluated its antitumor effect in a clinically relevant animal model of metastatic @entity0 . METHODS: 2*10(8) particles of a @entity7 vector expressing interleukin-12 ( @entity8 -IL-12) and/or 2*10(7) units of an aroC (-) @entity6 (LVR01) were injected into 4T1 @entity3 nodules orthotopically implanted in @entity4 . @entity3 were surgically resected and long-term survival was determined. IL-12 and interferon-y were quantified by Enzyme-Linked ImmunoSorbent Assay, bacteria was visualized by inmunohistochemistry and the number of lung @entity2 was calculated with a clonogenic assay. RESULTS: @entity8 -IL-12 and LVR01 timely inoculated and followed by surgical resection of @entity3 succeeded in complete inhibition of lethal lung @entity2 and long-term survival in 90% of treated @entity4 . The combined therapy was markedly synergistic compared to each treatment alone, since @entity8 -IL-12 monotherapy showed a potent antiangiogenic effect, being able to inhibit @entity3 growth and extend survival, but could not prevent establishment of distant @entity2 and @entity5 of @entity3 -excised animals. On the other hand, LVR01 alone also showed a significant, although limited, antitumor potential, despite its ability to invade @entity0 cells and induce granulocyte recruitment. The efficacy of the combined therapy depended on the order in which both factors were administered; inasmuch the therapeutic effect was only observed when @entity8 -IL-12 was administered previous to LVR01, whereas administration of LVR01 before @entity8 -IL-12 had negligible antitumor activity. Moreover, pre-treatment with LVR01 seemed to suppress @entity8 -IL-12 antiangiogenic effects associated to lower IL-12 expression in this group. Re-challenged @entity4 were unable to reject a second 4T1 @entity3 ; however 100% of them could be totally cured by applying the same neoadjuvant combined regimen. To our knowledge, these are the most encouraging results obtained to date in a post-operatory setting using the highly aggressive 4T1 animal model. CONCLUSIONS: @entity8 -IL-12-based gene therapy combined with @entity6 LVR01 neoadjuvant administration has a synergic antitumor effect and may be a promising therapeutic option to prevent and/or eradicate pre-operatory @entity2 in locally advanced @entity0 .

title: Neoadjuvant administration of @entity7 expressing interleukin-12 combined with attenuated XXXX eradicates @entity0 @entity2 and achieves long-term survival in immunocompetent @entity4 .

answer: @entity6


abstract: Baboon serum samples were resolved by starch gel electrophoresis and @entity1 gradient gel electrophoresis and stained with @entity2 substrates for esterase activity. An esterase that hydrolyzed @entity6 in preference to @entity4 was found in very high activities in some individuals but not others. It migrated just cathodal of the albumin band in starch gels. In @entity1 gradient gels, it co-migrated with albumin and had an apparent molecular weight of approximately 65,000 daltons. Electrophoretic analysis by gel electrophoresis of random serum samples from male and female @entity3 indicated that this esterase was present only in the sera of pregnant @entity3 . Further investigation of serial samples collected from carefully monitored @entity3 confirmed that the amount of activity of this esterase was correlated with stage of pregnancy. Therefore, it was named @entity5 ( @entity5 ). @entity5 was detectable by gel electrophoresis and chromogenic staining techniques as early as day 30 of pregnancy; its activity gradually increased with progressive pregnancy and reached maximum activity near full term (182 days). Soon after parturition, the activity of @entity5 decreased rapidly and was not detected in maternal sera by day 14 postpartum. No evidence of @entity5 was detected in sera of pregnant @entity0 .

title: Pregnancy-associated esterase in sera of XXXX .

answer: @entity3